TargetMol

Benserazide

Product Code:
 
TAR-T1517L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1517L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1517L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1517L-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Benserazide is an inhibitor of dopa decarboxylase. It is often given with levodopa in the treatment of Parkinson's to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose.
CAS:
322-35-0
Formula:
C10H15N3O5
Molecular Weight:
257.24
Purity:
0.98
SMILES:
NC(CO)C(NNCC1=CC=C(O)C(O)=C1O)=O

References

1. Wan Y, Wu N, Song L, Wang X, Liu Z, Yuan W, Gan J. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease. Front Aging Neurosci. 2017 Oct 18;9:331. doi: 10.3389/fnagi.2017.00331. eCollection 2017. PubMed PMID: 29093677; PubMed Central PMCID: PMC5651254. 2. Wollmer E, Klein S. Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices. J Pharm Pharm Sci. 2017;20(0):258-269. doi: 10.18433/J3K923. PubMed PMID: 28810948. 3. Pellegrini C, Antonioli L, Colucci R, Tirotta E, Gentile D, Ippolito C, Segnani C, Levandis G, Cerri S, Blandini F, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, Fornai M. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. Neuropharmacology. 2017 Sep 1;123:22-33. doi: 10.1016/j.neuropharm.2017.05.016. Epub 2017 May 17. PubMed PMID: 28526609. 4. Li W, Zheng M, Wu S, Gao S, Yang M, Li Z, Min Q, Sun W, Chen L, Xiang G, Li H. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res. 2017 Apr 20;36(1):58. doi: 10.1186/s13046-017-0530-4. PubMed PMID: 28427443; PubMed Central PMCID: PMC5399312.